[{"orgOrder":0,"company":"Universiti Kebangsaan Malaysia Medical Centre","sponsor":"Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Kebangsaan Malaysia Medical Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia"},{"orgOrder":0,"company":"University of Zagreb","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CROATIA","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"University of Zagreb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"University of Zagreb \/ BioGaia Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Zagreb \/ BioGaia Pharma"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma"},{"orgOrder":0,"company":"Sisters of Mercy University Hospital","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Neurology","graph2":"Phase III","graph3":"Sisters of Mercy University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sisters of Mercy University Hospital \/ BioGaia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Sisters of Mercy University Hospital \/ BioGaia Pharma"},{"orgOrder":0,"company":"Linkoeping University","sponsor":"BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Immunology","graph2":"Phase II","graph3":"Linkoeping University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","highestDevelopmentStatusID":"8","companyTruncated":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping"},{"orgOrder":0,"company":"Ostergotland County Council","sponsor":"BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ostergotland County Council","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine"},{"orgOrder":0,"company":"NovoNatum Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NovoNatum Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoNatum Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NovoNatum Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Children's Investigational Research Program, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Children's Investigational Research Program, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Children's Investigational Research Program, LLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Children's Investigational Research Program, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Case Western Reserve University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Case Western Reserve University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Case Western Reserve University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Case Western Reserve University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Vastra Gotaland Region","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Vastra Gotaland Region","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Vastra Gotaland Region"}]

Find Clinical Drug Pipeline Developments & Deals for Lactobacillus Reuteri

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 21, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 15, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          April 03, 2023

                          Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in br...

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 22, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acqui...

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          January 24, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk,become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          November 01, 2022

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          August 23, 2022

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Universiti Kebangsaan Malaysia Medical Centre

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Universiti Kebangsaan Malaysia Medical Centre

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Sponsor : Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Helicobacter Infections.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 01, 2022

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank